(SAN) Sanofi - Overview
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0000120578
Stock: Immunology, Vaccines, Oncology, Neurology, Rare Diseases
Total Rating 39
Risk 89
Buy Signal -1.10
| Risk 5d forecast | |
|---|---|
| Volatility | 22.1% |
| Relative Tail Risk | -6.21% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.06 |
| Alpha | -31.97 |
| Character TTM | |
|---|---|
| Beta | 0.334 |
| Beta Downside | 0.336 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.59% |
| CAGR/Max DD | -0.09 |
EPS (Earnings per Share)
Revenue
Description: SAN Sanofi March 01, 2026
Sanofi (SAN) is a global biopharma company that discovers, develops, manufactures, and markets therapeutic solutions across immunology, inflammation, rare diseases, neurology, oncology, and a broad vaccine portfolio-including pediatric, respiratory syncytial virus, hexavalent, influenza, COVID-19 (Nuvaxovid), and travel/endemic vaccines. The firm maintains an extensive partnership network, collaborating with firms such as Exscientia, Atomwise, Insilico Medicine, Kymera Therapeutics, Nurix Therapeutics, Denali Therapeutics, and Teva to advance small-molecule oncology agents, AI-driven drug design, protein degraders, and genome-editing technologies.
In FY 2023 Sanofi reported €38.5 billion in total revenue, with a 8 % year-over-year increase in vaccine sales driven by heightened demand for COVID-19 boosters and RSV products. R&D spending reached €5.7 billion, supporting a pipeline that now includes 12 late-stage candidates, three of which target rare neurological disorders. The pharmaceutical sector continues to be buoyed by an aging global population and rising prevalence of chronic inflammatory diseases, which are key economic drivers for Sanofi’s specialty medicines.
For a deeper quantitative assessment, consider reviewing Sanofi’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 10.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.90 > 1.0 |
| NWC/Revenue: 4.48% < 20% (prev 29.53%; Δ -25.05% < -1%) |
| CFO/TA 0.16 > 3% & CFO 20.32b > Net Income 10.62b |
| Net Debt (14.14b) to EBITDA (11.07b): 1.28 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.22b) vs 12m ago -2.65% < -2% |
| Gross Margin: 71.74% > 18% (prev 0.70%; Δ 7104 % > 0.5%) |
| Asset Turnover: 44.87% > 50% (prev 34.24%; Δ 10.64% > 0%) |
| Interest Coverage Ratio: 13.98 > 6 (EBITDA TTM 11.07b / Interest Expense TTM 563.0m) |
Altman Z'' 3.58
| A: 0.02 (Total Current Assets 30.95b - Total Current Liabilities 28.35b) / Total Assets 126.81b |
| B: 0.53 (Retained Earnings 66.88b / Total Assets 126.81b) |
| C: 0.06 (EBIT TTM 7.87b / Avg Total Assets 129.80b) |
| D: 1.26 (Book Value of Equity 69.32b / Total Liabilities 55.10b) |
| Altman-Z'' Score: 3.58 = A |
Beneish M -3.65
| DSRI: 0.03 (Receivables 397.0m/10.63b, Revenue 58.25b/45.47b) |
| GMI: 0.98 (GM 71.74% / 70.04%) |
| AQI: 1.12 (AQ_t 0.67 / AQ_t-1 0.59) |
| SGI: 1.28 (Revenue 58.25b / 45.47b) |
| TATA: -0.08 (NI 10.62b - CFO 20.32b) / TA 126.81b) |
| Beneish M-Score: -3.65 (Cap -4..+1) = AAA |
What is the price of SAN shares?
As of March 04, 2026, the stock is trading at EUR 79.86 with a total of 2,877,312 shares traded.
Over the past week, the price has changed by -0.93%, over one month by -1.50%, over three months by -6.75% and over the past year by -22.57%.
Over the past week, the price has changed by -0.93%, over one month by -1.50%, over three months by -6.75% and over the past year by -22.57%.
Is SAN a buy, sell or hold?
Sanofi has no consensus analysts rating.
What are the forecasts/targets for the SAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 98.5 | 23.3% |
| Analysts Target Price | - | - |
SAN Fundamental Data Overview February 28, 2026
Market Cap USD = 115.19b (97.67b EUR * 1.1794 EUR.USD)
P/E Trailing = 20.0695
P/E Forward = 10.1317
P/S = 2.0906
P/B = 1.5108
P/EG = 0.7851
Revenue TTM = 58.25b EUR
EBIT TTM = 7.87b EUR
EBITDA TTM = 11.07b EUR
Long Term Debt = 14.25b EUR (from longTermDebt, last quarter)
Short Term Debt = 4.61b EUR (from shortTermDebt, last quarter)
Debt = 21.80b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.14b EUR (from netDebt column, last quarter)
Enterprise Value = 111.80b EUR (97.67b + Debt 21.80b - CCE 7.66b)
Interest Coverage Ratio = 13.98 (Ebit TTM 7.87b / Interest Expense TTM 563.0m)
EV/FCF = 6.88x (Enterprise Value 111.80b / FCF TTM 16.25b)
FCF Yield = 14.54% (FCF TTM 16.25b / Enterprise Value 111.80b)
FCF Margin = 27.90% (FCF TTM 16.25b / Revenue TTM 58.25b)
Net Margin = 18.22% (Net Income TTM 10.62b / Revenue TTM 58.25b)
Gross Margin = 71.74% ((Revenue TTM 58.25b - Cost of Revenue TTM 16.46b) / Revenue TTM)
Gross Margin QoQ = 69.80% (prev 74.09%)
Tobins Q-Ratio = 0.88 (Enterprise Value 111.80b / Total Assets 126.81b)
Interest Expense / Debt = -0.43% (Interest Expense -93.0m / Debt 21.80b)
Taxrate = 14.11% (332.0m / 2.35b)
NOPAT = 6.76b (EBIT 7.87b * (1 - 14.11%))
Current Ratio = 1.09 (Total Current Assets 30.95b / Total Current Liabilities 28.35b)
Debt / Equity = 0.31 (Debt 21.80b / totalStockholderEquity, last quarter 71.38b)
Debt / EBITDA = 1.28 (Net Debt 14.14b / EBITDA 11.07b)
Debt / FCF = 0.87 (Net Debt 14.14b / FCF TTM 16.25b)
Total Stockholder Equity = 72.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.18% (Net Income 10.62b / Total Assets 126.81b)
RoE = 14.71% (Net Income TTM 10.62b / Total Stockholder Equity 72.18b)
RoCE = 9.11% (EBIT 7.87b / Capital Employed (Equity 72.18b + L.T.Debt 14.25b))
RoIC = 7.37% (NOPAT 6.76b / Invested Capital 91.72b)
WACC = 5.78% (E(97.67b)/V(119.46b) * Re(7.15%) + D(21.80b)/V(119.46b) * Rd(-0.43%) * (1-Tc(0.14)))
Discount Rate = 7.15% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.33%
[DCF] Terminal Value 88.43% ; FCFF base≈15.02b ; Y1≈18.53b ; Y5≈31.55b
[DCF] Fair Price = 749.2 (EV 918.77b - Net Debt 14.14b = Equity 904.63b / Shares 1.21b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -22.25 | EPS CAGR: -6.13% | SUE: 0.40 | # QB: 0
Revenue Correlation: 36.76 | Revenue CAGR: 25.75% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.83 | Chg7d=+0.004 | Chg30d=+0.105 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=8.38 | Chg7d=+0.014 | Chg30d=-0.015 | Revisions Net=+3 | Growth EPS=+7.0% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=8.91 | Chg7d=+0.003 | Chg30d=-0.032 | Revisions Net=-2 | Growth EPS=+6.4% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.0% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = +4.4% (Analyst 7.4% - Implied 3.0%)
P/E Trailing = 20.0695
P/E Forward = 10.1317
P/S = 2.0906
P/B = 1.5108
P/EG = 0.7851
Revenue TTM = 58.25b EUR
EBIT TTM = 7.87b EUR
EBITDA TTM = 11.07b EUR
Long Term Debt = 14.25b EUR (from longTermDebt, last quarter)
Short Term Debt = 4.61b EUR (from shortTermDebt, last quarter)
Debt = 21.80b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.14b EUR (from netDebt column, last quarter)
Enterprise Value = 111.80b EUR (97.67b + Debt 21.80b - CCE 7.66b)
Interest Coverage Ratio = 13.98 (Ebit TTM 7.87b / Interest Expense TTM 563.0m)
EV/FCF = 6.88x (Enterprise Value 111.80b / FCF TTM 16.25b)
FCF Yield = 14.54% (FCF TTM 16.25b / Enterprise Value 111.80b)
FCF Margin = 27.90% (FCF TTM 16.25b / Revenue TTM 58.25b)
Net Margin = 18.22% (Net Income TTM 10.62b / Revenue TTM 58.25b)
Gross Margin = 71.74% ((Revenue TTM 58.25b - Cost of Revenue TTM 16.46b) / Revenue TTM)
Gross Margin QoQ = 69.80% (prev 74.09%)
Tobins Q-Ratio = 0.88 (Enterprise Value 111.80b / Total Assets 126.81b)
Interest Expense / Debt = -0.43% (Interest Expense -93.0m / Debt 21.80b)
Taxrate = 14.11% (332.0m / 2.35b)
NOPAT = 6.76b (EBIT 7.87b * (1 - 14.11%))
Current Ratio = 1.09 (Total Current Assets 30.95b / Total Current Liabilities 28.35b)
Debt / Equity = 0.31 (Debt 21.80b / totalStockholderEquity, last quarter 71.38b)
Debt / EBITDA = 1.28 (Net Debt 14.14b / EBITDA 11.07b)
Debt / FCF = 0.87 (Net Debt 14.14b / FCF TTM 16.25b)
Total Stockholder Equity = 72.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.18% (Net Income 10.62b / Total Assets 126.81b)
RoE = 14.71% (Net Income TTM 10.62b / Total Stockholder Equity 72.18b)
RoCE = 9.11% (EBIT 7.87b / Capital Employed (Equity 72.18b + L.T.Debt 14.25b))
RoIC = 7.37% (NOPAT 6.76b / Invested Capital 91.72b)
WACC = 5.78% (E(97.67b)/V(119.46b) * Re(7.15%) + D(21.80b)/V(119.46b) * Rd(-0.43%) * (1-Tc(0.14)))
Discount Rate = 7.15% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.33%
[DCF] Terminal Value 88.43% ; FCFF base≈15.02b ; Y1≈18.53b ; Y5≈31.55b
[DCF] Fair Price = 749.2 (EV 918.77b - Net Debt 14.14b = Equity 904.63b / Shares 1.21b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -22.25 | EPS CAGR: -6.13% | SUE: 0.40 | # QB: 0
Revenue Correlation: 36.76 | Revenue CAGR: 25.75% | SUE: 0.07 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.83 | Chg7d=+0.004 | Chg30d=+0.105 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=8.38 | Chg7d=+0.014 | Chg30d=-0.015 | Revisions Net=+3 | Growth EPS=+7.0% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=8.91 | Chg7d=+0.003 | Chg30d=-0.032 | Revisions Net=-2 | Growth EPS=+6.4% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.0% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = +4.4% (Analyst 7.4% - Implied 3.0%)